<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972682</url>
  </required_header>
  <id_info>
    <org_study_id>MCOH62-07-08-21</org_study_id>
    <nct_id>NCT04972682</nct_id>
  </id_info>
  <brief_title>[SENTRY] Sentinel Lymph Node Biopsy Predictive Value in Endometrial Cancer of Low and Intermediate Risk</brief_title>
  <acronym>SENTRY</acronym>
  <official_title>Sentinel Lymph Node Biopsy Predictive Value in Endometrial Cancer of Low and Intermediate Risk: a Single-center Prospective Descriptive Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow City Oncology Hospital No. 62</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moscow City Oncology Hospital No. 62</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymphadenectomy performed for endometrial cancer influences the decision on adjuvant therapy.&#xD;
      The aim of this study is to evaluate the rate of change in postoperative treatment based on&#xD;
      the result of sentinel lymph node biopsy (SLNB).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single-center prospective descriptive cohort study without a control group.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postoperative treatment</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The rate of change in postoperative treatment based on the SLNB results and postoperative histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease stage</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The rate of change in disease stage based on SLNB results and postoperative histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral SLN detection</measure>
    <time_frame>At the end of the surgery - 1 day</time_frame>
    <description>The rate of bilateral SLN detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative complications</measure>
    <time_frame>At the end of the surgery - 1 day</time_frame>
    <description>The rate and details of intraoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Early postoperative morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Early postoperative mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphatic edema</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The rate of lymphatic edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Time to recurrence in the pelvis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Endometrial Adenocarcinoma</condition>
  <condition>Endometrial Cancer Stage I</condition>
  <condition>Endometrial Cancer Stage II</condition>
  <condition>Endometrial Endometrioid Adenocarcinoma</condition>
  <condition>Sentinel Lymph Node</condition>
  <condition>Hysterectomy</condition>
  <condition>Laparoscopic Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Laparoscopic hysterectomy with sentinel lymph node biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm includes patients with endometrial adenocarcinoma of low and intermediate risk who will undergo a laparoscopic hysterectomy and sentinel lymph node biopsy (SLNB) performed with near-infrared-guided surgery using indocyanine green (ICG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic hysterectomy with sentinel lymph node biopsy</intervention_name>
    <description>Patients will undergo a laparoscopic hysterectomy and sentinel lymph node (SLN) biopsy performed with near-infrared-guided surgery using indocyanine green (ICG). The standard dilution of the drug is 2.5 mg/mL. One milliliter of the diluted drug will be injected into the cervix at 3 and 9 o'clock (total dose - 5 mg) to a depth of 5-10 mm immediately after the onset of anesthesia. Then diagnostic laparoscopy and revision of the abdomen and pelvis will be performed and Image 1S equipment (KARL STORZ©, Tuttlingen, Germany) will be used for this procedure. After revision, fluorescence in the near-infrared spectrum will be determined. Mapping is considered successful when the lymphatic ducts with at least one lymph node are identified. Then the detected SLN will be harvested and total hysterectomy will be performed. Urgent histological examination of the SLN is optional but can be performed at the discretion of the surgeon. If metastasis is detected in the SLN, lymphadenectomy is allowed.</description>
    <arm_group_label>Laparoscopic hysterectomy with sentinel lymph node biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Histologically verified low-grade endometrial adenocarcinoma of the endometrium&#xD;
             (G1-G2)&#xD;
&#xD;
          -  Stage IA (FIGO 2009) according to MRI (CT, ultrasound)&#xD;
&#xD;
          -  Stage IB and II (FIGO 2009) when lymphadenectomy is contraindicated&#xD;
&#xD;
          -  No contraindications for surgery&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  Signs of tumor spread outside the corpus uteri&#xD;
&#xD;
          -  No signs of tumor invasion into the myometrium&#xD;
&#xD;
          -  High-grade tumor (G3)&#xD;
&#xD;
          -  Bokhman type 2 tumor (serous adenocarcinoma, clear cell adenocarcinoma,&#xD;
             carcinosarcoma, endometrial stromal sarcoma, etc.)&#xD;
&#xD;
          -  Preoperative treatment of endometrial cancer (radiation therapy, chemotherapy or&#xD;
             hormone therapy)&#xD;
&#xD;
          -  Prior pelvic or retroperitoneal lymphadenectomy&#xD;
&#xD;
          -  Prior surgery on the uterus and uterine appendages (except for cesarean section,&#xD;
             tubectomy, ovariectomy, ovarian resection, ovarian biopsy, ovarian cauterization)&#xD;
&#xD;
          -  Surgical treatment is contraindicated&#xD;
&#xD;
          -  Allergy to iodine-containing drugs&#xD;
&#xD;
          -  No signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pavel Sorokin, MD</last_name>
    <phone>+79111352789</phone>
    <email>sor-pavel@ya.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svetlana Kulikova, MD</last_name>
    <phone>+79036266741</phone>
    <email>s_s72@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecologic Oncology, Moscow City Oncology Hospital No. 62</name>
      <address>
        <city>Istra</city>
        <state>Moscow Region</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Sorokin, MD</last_name>
      <phone>+79036266741</phone>
      <email>sor-pavel@ya.ru</email>
    </contact>
    <contact_backup>
      <last_name>Svetlana Kulikova, MD</last_name>
      <phone>+79111352789</phone>
      <email>s_s72@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Svetlana Kulikova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Sorokin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anton Buchaka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrei Nikiforchin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitry Utkin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daria Bystritskaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikhail Novozhilov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Endometrial Adenocarcinoma</keyword>
  <keyword>Sentinel Lymph Node Biopsy</keyword>
  <keyword>Laparoscopic Hysterectomy</keyword>
  <keyword>Adjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

